Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Haematologica. 2010 Dec;95(12):2072-9. doi: 10.3324/haematol.2010.028639. Epub 2010 Aug 26.
Numerous subsets of patients with chronic lymphocytic leukemia display similar immunoglobulin gene usage with almost identical complementarity determining region 3 sequences. Among IGHV4-34 cases, two such subsets with "stereotyped" B-cell receptors were recently identified, i.e. subset #4 (IGHV4-34/IGKV2-30) and subset #16 (IGHV4-34/IGKV3-20). Subset #4 patients appear to share biological and clinical features, e.g. young age at diagnosis and indolent disease, whereas little is known about subset #16 at a clinical level.
We investigated the global gene expression pattern in sorted chronic lymphocytic leukemia cells from 25 subset/non-subset IGHV4-34 patients using Affymetrix gene expression arrays.
Although generally few differences were found when comparing subset to non-subset 4/16 IGHV4-34 cases, distinct gene expression profiles were revealed for subset #4 versus subset #16. The differentially expressed genes, predominantly with lower expression in subset #4 patients, are involved in important cell regulatory pathways including cell-cycle control, proliferation and immune response, which may partly explain the low-proliferative disease observed in subset #4 patients.
Our novel data demonstrate distinct gene expression profiles among patients with stereotyped IGHV4-34 B-cell receptors, providing further evidence for biological differences in the pathogenesis of these subsets and underscoring the functional relevance of subset assignment based on B-cell receptor sequence features.
许多慢性淋巴细胞白血病患者亚群表现出相似的免疫球蛋白基因使用情况,几乎具有相同的互补决定区 3 序列。在 IGHV4-34 病例中,最近确定了两个具有“定型”B 细胞受体的此类亚群,即亚群 #4(IGHV4-34/IGKV2-30)和亚群 #16(IGHV4-34/IGKV3-20)。亚群 #4 患者似乎具有相似的生物学和临床特征,例如诊断时年龄较小和惰性疾病,而在临床水平上对亚群 #16 知之甚少。
我们使用 Affymetrix 基因表达谱芯片研究了 25 例亚群/非亚群 IGHV4-34 患者分选的慢性淋巴细胞白血病细胞的全局基因表达模式。
尽管在比较亚群与非亚群 4/16 IGHV4-34 病例时通常发现很少差异,但亚群 #4 与亚群 #16 之间揭示了明显不同的基因表达谱。差异表达的基因,主要在亚群 #4 患者中表达较低,涉及重要的细胞调节途径,包括细胞周期控制、增殖和免疫反应,这可能部分解释了亚群 #4 患者观察到的低增殖性疾病。
我们的新数据表明,具有定型 IGHV4-34 B 细胞受体的患者具有明显不同的基因表达谱,为这些亚群发病机制中的生物学差异提供了进一步证据,并强调了基于 B 细胞受体序列特征进行亚群分配的功能相关性。